Moderna raised $2.6 billion to support its cancer strategy after securing a “big win” in a key study, according to the report. The financing reflects investor demand to fund late-stage and platform work as Moderna continues to expand beyond infectious disease into oncology. The upsize indicates the company is moving aggressively on pipeline execution and manufacturing scale, while preserving flexibility for trial reads across tumor settings. The same item also notes that another biotech’s shares fell after trial data were “inadvertently” published before a medical meeting, underscoring the market sensitivity to timing and information control. The Moderna capital plan will likely influence near-term execution timelines for immunology- and mRNA-based cancer programs and supply commitments.